COMPANY PROFILE

Corixa

Explore full profile

Corixa Corporation - powering the immune system

Seattle, United StatesFounded 1994Biotech & Life Sciences

Valuation $100–250M Last recorded · 2005

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Corixa

CoulterPharm is a pioneering biotechnology company specializing in the development of immunotherapeutics aimed at treating and preventing autoimmune diseases, cancer, and infectious diseases. The company leverages advanced technology platforms to understand and direct the immune system, creating targeted therapies that address critical health challenges. CoulterPharm serves a diverse range of clients, including healthcare providers, research institutions, and pharmaceutical companies, operating primarily in the biotech and pharmaceutical markets. The business model revolves around the research, development, and commercialization of its proprietary therapeutic products. Revenue is generated through product sales, research grants, and strategic partnerships with other industry players. CoulterPharm's commitment to innovation and scientific excellence positions it as a leader in the field of immunotherapy.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 1994
Headquarters: Seattle, United States
Open positions: None listed
Dealroom signal: 53.8/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Diabetes, Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITION✓Exit	May 2005	$233M	$233M	GSK	—
IPO✓Exit	Oct 1997	$0	—	Undisclosed	—

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Corixa website traffic

Latest recorded traffic for Corixa is 0 monthly website visits.

Latest monthly visits0

Monthly website visitsApr 2016–Oct 2020

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
EXExonateTopical small-molecule therapeutics for retinal vascular diseases	Cambridge, United Kingdom	Operational	17	$12M	$7.6M
OTOrexigen TherapeuticsBiopharmaceutical company focused on the treatment of obesity	San Diego, United States	Acquired
SPSignpath PharmaBiotechnology company developing therapeutics using curcuminoids extracted from the root of the curcuma longa plant	Quakertown, United States	Operational
IPIdenix PharmaceuticalsDiscovery and development of drugs for the treatment of human viral diseases	Cambridge, United States	Acquired
PEPepticomAn Artificial Intelligence (AI) company for the discovery of novel molecules in the Pharmaceutical and Agricultural markets	Jerusalem, Israel	Operational
KTKlotho TherapeuticsFocused on development and commercialization of recombinant human Klotho proteins to prevent and treat kidney disease and other diseases	San Diego, United States	Operational
SYSyrrxDrug discovery company committed to redefining the way medicines are discovered	San Diego, United States	Acquired
BIBiomXCustomized phage therapies to eradicate harmful bacteria in chronic diseases	Ness Ziona, Israel	Operational